MAIA Biotechnology Announces Open Market Purchases by CEO and Director
Rhea-AI Summary
MAIA Biotechnology (NYSE American: MAIA) reported insider open market share purchases by its founder and CEO Vlad Vitoc and Director Stan V. Smith.
Vitoc bought about 72,700 shares at $1.3877 and Smith about 75,000 shares at $1.336 on June 6, 2026, bringing directors and officers’ ownership to 20.46%. The company is advancing its telomere-targeting immuno-oncology platform, including the ateganosine program for advanced non-small cell lung cancer.
Positive
- CEO Vlad Vitoc purchased approximately 72,700 MAIA shares at $1.3877
- Director Stan V. Smith purchased approximately 75,000 MAIA shares at $1.336
- Directors and officers collectively hold a 20.46% stake in MAIA
Negative
- None.
News Market Reaction – MAIA
In the Jun 2 session, MAIA gained 3.85%, reflecting a moderate positive market reaction. Argus tracked a peak move of +11.8% during that session. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 01 | ASCO Phase 3 poster | Positive | -6.5% | Trial-in-progress poster for pivotal Phase 3 THIO-104 in resistant NSCLC. |
| Apr 16 | Phase 2 US expansion | Positive | -6.3% | First U.S. site activated for THIO-101 Phase 2 expansion and added U.S. access. |
| Apr 08 | Capital raise funding trial | Neutral | +3.3% | $33M common stock offering expected to fully fund pivotal Phase 3 trial. |
| Mar 31 | Phase 2 survival data | Positive | +6.9% | Eight NSCLC patients showed overall survival beyond two years in THIO-101. |
| Mar 04 | Underwritten equity offering | Negative | -1.9% | $30M underwritten offering of 20M shares at $1.50 to fund trials. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent clinically focused announcements often saw negative price reactions, while strong survival data and financing clarity aligned with positive moves.
Over the last few months, MAIA reported multiple milestones around its telomere-targeting ateganosine programs. On Mar 4, a $30M stock offering funded clinical work. Subsequent updates on Phase 2 survival data and Phase 3 planning in March and April generally saw mixed but sometimes positive reactions. More recent clinical communications in April and at ASCO on Jun 1 coincided with declines, suggesting the market had become more cautious on news flow ahead of today’s insider purchase disclosure.
Key Terms
open market purchases financial
telomere-targeting medical
immuno-oncology medical
non-small cell lung cancer medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
CHICAGO, June 02, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that its founder and CEO Vlad Vitoc, M.D. and Director Stan V. Smith, Ph.D. have increased their ownership positions through open market purchases.
Approximately 72,700 shares of MAIA common stock were purchased by Dr. Vitoc on June 6, 2026, at an average common stock price of
“Our continuing investments underscore our strong confidence in the telomere-targeting immuno-oncology platform we’ve established,” said Dr. Vitoc. “As the ateganosine program advances toward later-stage development, we believe ateganosine could become an important new standard of care for patients with advanced non-small cell lung cancer.”
“MAIA continues to advance what I believe is a differentiated approach to cancer treatment with strong scientific rationale and encouraging clinical momentum,” Dr. Smith added. “I’m a strong believer in the incredible potential future that MAIA has in contributing to the patients and investors alike.”
To date, directors and officers of MAIA hold a
About Ateganosine
Ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.
About MAIA Biotechnology, Inc.
MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.
Forward Looking Statements
MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.
Investor Relations Contact
+1 (872) 270-3518
ir@maiabiotech.com
